Edwards Lifesciences Financial Diagnostics

Edwards Lifesciences Corporation -- USA Stock  

USD 104.98  2.11  1.97%

Edwards Lifesciences Corporation diagnostics interface makes it easy to digest most current publicly released information about Edwards Lifesciences as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Edwards Lifesciences price relationship with some important fundamental indicators such as market cap and management efficiency.
The company has Price/Earnings To Growth (PEG) ratio of 1.74. Edwards Lifesciences Corporation had not issued any dividends in recent years. This company had 2:1 split on 2015-12-14. Edwards Lifesciences Corporationration offer solutions and technologies to treat structural heart disease and critically ill patients worldwide. To learn more about EDWARDS LIFESCIEN call Michael Mussallem at 949 250-2500 or check out www.edwards.com.

Edwards Lifesciences Alerts

Edwards Lifesciences generates negative expected return over the last 30 days
Edwards Lifesciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its debt commitments
Latest headline from ledgergazette.com: ACG Wealth Takes Position in Edwards Lifesciences Corporation

Edwards Lifesciences Upcoming Events

Upcoming Quarterly ReportApril 25, 2017
Next Earnings ReportJuly 25, 2017

Edwards Lifesciences EPS Estimate

EPSEstimate Date
Quarterly Estimate0.83April 25, 2017

Edwards Lifesciences SEC Filings

Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event
Financial Statements and Exhibits. Departure of Directors or Certain Offices; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares21.1 M2.3 B
Blackrock IncCommon Shares15.1 M1.6 B
State Street CorpCommon Shares8.8 M966.7 M
Sands Capital Management LlcCommon Shares7.2 M791 M
Wellington Management Group LlpCommon Shares5.7 M623.1 M
Alliancebernstein LpCommon Shares5.6 M610.4 M
Bank Of New York Mellon CorpCommon Shares5.2 M568.8 M

Market Capitalization

The company currently falls under 'Large-Cap' category with market capitalization of 22.66 B.

Profitablity

The company has Net Profit Margin (PM) of 22.16 % which may suggest that it has a good control over its expenditures, executes well on its competitive polices, or have a solid pricing strategies. This is very large. Likewise, it shows Net Operating Margin (NOM) of 29.95 % which signify that for every $100 of sales it has a net operating income of 0.3.

Management Efficiency

Edwards Lifesciences Corporation has Return on Asset (ROA) of 13.17 % which means that for every $100 of asset it generated profit of $13.17. This is typical in the industry. Likewise, it shows return on total equity (ROE) of 26.47 % which means that it produced $26.47 on every 100 dollars invested by current stockholders.

Stock Holders for Edwards Lifesciences

Information
Ratio
Value
At Risk
ColumbiaColumbia Mid Cap Growth C 0.0012 (0.79) 
ColumbiaColumbia Mid Cap Growth R 0.0008 (0.77) 
NuveenNuveen Symphony Mid Cap Core I(0.13) (0.69) 
WSCMXWellington Shields All Cap A(0.15) (0.82) 
WaddellWaddell Reed New Concepts C 0.13 (0.62) 
Ivy MidIvy Mid Cap Growth Y 0.14 (0.57) 
Ivy MidIvy Mid Cap Growth R 0.14 (0.6) 
Ivy MidIvy Mid Cap Growth C 0.14 (0.59) 
Ivy MidIvy Mid Cap Growth B 0.14 (0.57) 
Ivy MidIvy Mid Cap Growth A 0.14 (0.59) 
WellsWells Fargo Enterprise Inst 0.0493 (0.79) 
WellsWells Fargo Enterprise R6 0.051 (0.77) 
WellsWells Fargo Enterprise C 0.0433 (0.8) 
VanguardVanguard Index Funds Vanguard Mid Cap Growth ETF 0.00  0.00 
VanguardVanguard Mid Cap Growth ETF 0.0262 (0.55) 
VanguardVanguard Mid Cap ETF(0.0572) (1.02) 
VanguardVanguard Mid Cap ETF(0.059) (0.55) 
VanguardVanguard Mid Cap Growth Index Admiral 0.0201 (0.58) 
VanguardVanguard Mid Cap Growth Index Investor 0.0274 (0.57) 
VanguardVanguard Mid Cap Index Institutional(0.0799) (0.51) 

Technical Drivers

Edwards Lifesciences Corporation shows Coefficient Of Variation of (1,256) and Mean Deviation of 1.11. Edwards Lifesciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm future prices. In plain English you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for Edwards Lifesciences Corporation which can be compared to its rivals. Please confirm Edwards Lifesciences Information Ratio, Potential Upside as well as the relationship between Potential Upside and Kurtosis to decide if Edwards Lifesciences is priced favorably providing market reflects its regular price of 104.98 per share. Given that Edwards Lifesciences has Jensen Alpha of (0.065155), we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself at future point.

Edwards Lifesciences Price Movement Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of seventeen. Edwards Lifesciences Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Edwards Lifesciences price patterns. View also all equity analysis or get more info about inverse tangent over price movement math transform indicator.

Stakeholder Activities

Edwards Lifesciences Insider Trading
Michael Mussallem 3 days ago via Macroaxis 
Exercise or conversion by Michael Mussallem of 35000 shares of Edwards Lifesciences subject to Rule 16b-3
Reindl Robert C few days ago via Macroaxis 
Payment of 721 shares by Reindl Robert C of Edwards Lifesciences subject to Rule 16b-3
Larry Wood over a week ago via Macroaxis 
Sale by Larry Wood of 1664 shares of Edwards Lifesciences
Huimin Wang over a week ago via Macroaxis 
Exercise or conversion by Huimin Wang of 4850 shares of Edwards Lifesciences subject to Rule 16b-3
Barbara McNeil over a week ago via Macroaxis 
Purchase by Barbara McNeil of 158 shares of Edwards Lifesciences
Nevinny Corinne H over a week ago via Macroaxis 
Sale by Nevinny Corinne H of 3000 shares of Edwards Lifesciences
Kehl John H Jr over a week ago via Macroaxis 
Sale by Kehl John H Jr of 1000 shares of Edwards Lifesciences
Michael Mussallem over two weeks ago via Macroaxis 
Exercise or conversion by Michael Mussallem of 32900 shares of Edwards Lifesciences subject to Rule 16b-3
Donald Bobo over three weeks ago via Macroaxis 
Acquisition by Donald Bobo of 3650 shares of Edwards Lifesciences subject to Rule 16b-3
Huimin Wang over three weeks ago via Macroaxis 
Exercise or conversion by Huimin Wang of 6250 shares of Edwards Lifesciences subject to Rule 16b-3
Mccauley Christine Z over a month ago via Macroaxis 
Exercise or conversion by Mccauley Christine Z of 10000 shares of Edwards Lifesciences subject to Rule 16b-3
Huimin Wang over a month ago via Macroaxis 
Sale by Huimin Wang of 13700 shares of Edwards Lifesciences

Bonds

Edwards Lifesciences Outstanding Bonds

Corporate Filings

Edwards Lifesciences Corporate Reports
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations